ONCY Stock Forecast & Price Target

Oncolytics Biotech is supported by a sharpened GI-focused strategy that concentrates capital on pelareorep’s most advanced opportunities, while preserving optionality in SCAC and mPDAC through FDA-aligned pathways and potential partnerships. The most important fundamental driver is the REO 033 program, where written FDA feedback appears to align with a pivotal Part B expansion, and Part A is already progressing with roughly half of planned sites activated, more than 20 patients pre-identified, and an initial tumor response update expected by year-end 2026. Financially, the company remains early-stage with $4.1 million in cash and cash equivalents as of June 30, so the investment case hinges on execution, regulatory de-risking, and continued access to capital through its ATM facility.

Oncolytics Biotech is facing a weak fundamental setup because its 2Q26 filing showed only $4.1 million of cash and cash equivalents at June 30, while management still does not expect that capital, even with ATM access, to fund planned operations for at least twelve months. The company also raised just $6.8 million net from ATM sales of about 7.9 million shares at an average price of $0.91, underscoring ongoing financing dependence and dilution risk as annual equity raises of $50 million to $100 million are modeled from 2026E-2029E. Meanwhile, development risk has increased as the SCAC program was deprioritized, the registrational protocol remains unfinished, GOBLET Cohort 4 timing is open-ended, and the modeled launch for pela in SCAC has been pushed to 2031E with probability of success cut to 10% from 40%.